Evaluation of Vitek 2 performance for identifying extended spectrum beta-lactamases in Enterobacteriaceae "other than Escherichia coli, Proteus mirabilis and Klebsiella spp";Valutazione della performance di Vitek 2 per la rilevazione delle beta-lattamasi a spettro esteso in Enterobaeteriaceae "other than Escherichia coli, Proteus mirabilis e Klebsiella spp"

Infezioni in Medicina

Volumn 14, Issue 4, 2006, Pages 216-226

  Diamante, Paola ^a   Camporese, Alessandro ^a  

^a S MARIA DEGLI ANGELI HOSPITAL   (Italy)

Author keywords

Enterobacteriaceae; Extended spectrum beta lactamases (ESBLs); Resistance

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZTREONAM; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CLAVULANIC ACID; EXTENDED SPECTRUM BETA LACTAMASE;

ARTICLE; CITROBACTER; CONTROLLED STUDY; ENTEROBACTERIACEAE; ENZYME ANALYSIS; ESCHERICHIA COLI; INTERMETHOD COMPARISON; KLEBSIELLA; KLEBSIELLA PNEUMONIAE; MORGANELLA MORGANII; NONHUMAN; PROTEUS; PROTEUS MIRABILIS; PROVIDENCIA STUARTII; SERRATIA MARCESCENS;

BACTERIOLOGICAL TECHNIQUES; BETA-LACTAMASES; ENTEROBACTERIACEAE; HUMANS;

EID: 33846668781     PISSN: 11249390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Cornaglia G., Luzzaro F., Pagani L. L'antibiogramma per le Enterobacteriaceae. In L'antibiogramma (Piccin Editore) 2000, pp 163-189, Padova.
2. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Sixteenth Informational Supplement. Document M100-S16. CLSI, Villanova, PA: 2006.
3. Camporese A., Tizianel G., Santini GF. Enterobatteri produttori di beta lattamasi a spettro esteso isolati a Pordenone: risultati di un semestre. Microbiologia Medica. 2 (14), 150, 1999.
4. Luzzaro F., Mezzatesta M., Mugnaioli C. et al. Trends in production of Extended-Spectrum β-lactamases among enterobacteria of medical interest: report of second Italian nationwide survey. J. Clin. Microbiol. 44, 659-1664, 2006.
5. Jacoby G.A., Munoz-Price L.S. The New β-Lactamases. N. Engl. J. Med. 352, 380-391, 2005.
6. Schwaber M.J., Raney P.M., Rasheed J.K. et al. Utility of NCCLS Guidelines for Identifying Extended-Spectrum ,-Lactamases in Non-Escherichia coli and Non-Klebsiella spp. of Enterobacteriaceae. J. Clin. Microbiol. 42, 294-98, 2004.
7. Barry J., Brown A., Ensor V. et al. Comparative evaluation of the Vitek 2 Advanced Expert System (AES) in five UK hospitals. J. Antimicrob. Chemother. 51, 1191-1202, 2003.
8. Queenan A.M., Foleno B., Gownley C. et al. Effects of inoculum and -lactamase activity in AmpC-and extended-spectrum -lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae clinical isolates tested by using NCCLS ESBL methodology. J. Clin. Microbiol. 42, 269-275, 2004.
9. Leverstein-van Hall M.A., Fluit A.C., Paauw A. et al. Evaluation of the Etest ESBL and the BD Phoenix, Vitek1,and Vitek2 Automated Instruments for Detection of Extended-Spectrum Beta-Lactameses in Multiresistant Escherichia coli and Klebsiella spp. J. Clin. Microbiol. 40, 3703-11, 2002.
10. Tenover F.C., Raney P. M., Williams P. P. et al. Evaluation of the NCCLS extended-spectrum β-lactamase confirmation methods for Escherichia coli with isolates collected during Project ICARE. J. Clin. Microbiol. 41, 3142-3146, 2003.
11. Thomson K. S. Controversies about extended-spectrum and AmpC beta-lactamases. Emerg. Infect. Dis. 7, 333-336, 2001.
12. Livermore D.M., Winstanley T.G., Shannon K.P. Interpretative reading: recognizing the unusual and inferring resistance mechanisms from resistance phenotypes. J. Antimicrob. Chemother. 48, 87-102, 2001.
13. Philippon A., Arlet G., Jacoby G.A. Plasmid-determined AmpC-type -lactamases. Antimicrob. Agents Chemother. 46, 1-11, 2002.
14. Camporese A. The impact of automation on organizational changes in a community hospital microbiology laboratory: the passage from a "biological" management to a "clinical" management. Infez. Med. 12(2), 118-125, 2004.
15. Bradford P. A. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin. Microbiol Rev. 14, 933-951, 2001.
16. Bush K. New β-lactamases in Gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. Clin. Infect. Dis. 32, 1085-1089, 2001.
17. Tenover F.C., Mohammed M.J., Stelling J. et al. Ability of laboratories to detect emerging antimicrobial resistance: proficiency testing and quality control results from the World Health Organization's external quality assurance system for antimicrobial susceptibility testing. J. Clin. Microbiol. 39, 241-250, 2001.
18. Essack S. Y. Laboratory detection of extended-spectrum β-lactamases (ESBLs)-the need for a reliable, reproducible method. Diagn. Microbiol. Infect. Dis. 37, 293-295, 2000.
19. Bisson G., Fishman N.O., Patel J.B. et al. Extended-spectrum -lactamase-producing Escherichia coli and Klebsiella species: risk factors for colonization and impact of antimicrobial formulary interventions on colonization prevalence. Inf. Contr. Hosp. Epidemiol. 23, 254-260, 2002.
20. Arpin C., Dubois V., Coulange L. et al. Extended-spectrum -lactamase-producing Enterobacteriaceae in community and private health care centers. Antimicrob. Ag. Chemother. 47, 3506-3514, 2003.
21. D'Agata E., Venkataraman L., DeGirolami P. et al. The molecular and clinical epidemiology of enterobacteriaceae-producing extended-spectrum -lactamase in a tertiary care hospital. J. Infect. 36, 279-285, 1998.
22. Medeiros A.A. Evolution and dissemination of - lactamases accelerated by generations of -lactam antibiotics. Clin. Infect. Dis. 24 (Suppl 1), 19-45, 1997.